Symptoms and General Pathology

All Conditions

Neoplasms

Recurrence

Carcinoma

Adenocarcinoma

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Head and Neck Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Cetuximab

Antineoplastic Agents, Immunological

Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors

NT219

Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma

NT219 and ERBITUX® - Dose Escalation

Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

NT219 and ERBITUX® - Expansion

Michael Schickler, PhD

This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

A Phase 1/2 Study With Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Incidence of treatment emergent adverse events with single agent NT219

Incidence of treatment emergent adverse events with NT219 administered in combination with ERBITUX®

Objective Response Rate when phase 2 dose of NT219 is used in combination with ERBITUX® in adults with recurrent and/or metastatic SCCHN

Area under the plasma concentration curve \[AUC\] of NT219

Maximum plasma concentration \[Cmax\] of NT219

Volume of distribution at stead-state \[Vss\] of NT219

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	NCT04474470	Solid Tumor, Ad... Squamous Cell C... Colorectal Aden... Metastatic Soli... Recurrent Solid... Head and Neck C...	NT219 NT219 and ERBIT... NT219 and ERBIT...	18 Years -	Purple Biotech Ltd.
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	NCT04474470	Solid Tumor, Ad... Squamous Cell C... Colorectal Aden... Metastatic Soli... Recurrent Solid... Head and Neck C...	NT219 NT219 and ERBIT... NT219 and ERBIT...	18 Years -	Purple Biotech Ltd.

Spots Global Cancer Trial Database for nt219

Every month we try and update this database with for nt219 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for nt219

Every month we try and update this database with for nt219 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for nt219 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.